A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer

2012 ◽  
Vol 15 (4) ◽  
pp. 363-369 ◽  
Author(s):  
Kazuhiro Nishikawa ◽  
Satoshi Morita ◽  
Takanori Matsui ◽  
Michiya Kobayashi ◽  
Yoji Takeuchi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Gastric Cancer ◽  
Randomized Phase Ii ◽  
Fluorinated Pyrimidines

Randomized phase II trial comparing 4 doublets as a front-line treatment in Asian patients with recurrent/metastatic gastric cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 4063-4063
Author(s):  
Hongjae Chon ◽  
Chan Kim ◽  
Minkyu Jung ◽  
Seungtaek Lim ◽  
Joo Hoon Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Gastric Cancer ◽  
Line Treatment ◽  
Front Line ◽  
Asian Patients ◽  
Randomized Phase Ii

Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil

2006 ◽  
Vol 17 (2) ◽  
pp. 225-229 ◽  
Author(s):  
Se Hoon Park ◽  
Woon Kee Lee ◽  
Min Chung ◽  
Yuna Lee ◽  
Sang Hoon Han ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Randomized Phase Ii

Phase II Trial of Etoposide (V), Adriamycin (A), and Cisplatinum (P) in Patients with Metastatic Gastric Cancer

1991 ◽  
Vol 14 (4) ◽  
pp. 357-358 ◽  
Author(s):  
Artur Katz ◽  
Rene C. Gansl ◽  
Sergio D. Simon ◽  
Joaquim Gama-Rodrigues ◽  
Dan Waitzberg ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Gastric Cancer

Phase II Trial of 4′-Epi-Doxorubicin in Locally Advanced or Metastatic Gastric Cancer

1988 ◽  
Vol 74 (3) ◽  
pp. 313-315 ◽  
Author(s):  
Eduardo Cazap ◽  
Roberto Estevez ◽  
Mario Bruno ◽  
Daniel Levy ◽  
Carlos Algamiz ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Gastric Adenocarcinoma ◽  
Phase Ii ◽  
Response Rate ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Metastatic Gastric Cancer ◽  
Phase Iii ◽  
Future Studies ◽  
Phase Iii Trials

Patients with locally advanced or metastatic gastric adenocarcinoma received an i.v. bolus of 4′-epi-doxorubicin, 75/mg/m2/cycle, every 21 days. Partial responses were observed in 5 of 23 evaluable patients (21.7%). Treatment was generally well tolerated and toxicity was mild. The response rate to epirubicin appears to be very similar to that reported for doxorubicin. Larger doses of epirubicin could be safely used in future studies, and further evaluation of epirubicin in phase III trials is indicated.

Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer

2019 ◽  
Vol 112 ◽  
pp. 20-28
Author(s):  
Chan Kim ◽  
Hong Jae Chon ◽  
Joo Hoon Kim ◽  
Minkyu Jung ◽  
Chung Mo Nam ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Gastric Cancer ◽  
Front Line ◽  
Asian Patients
Sign in / Sign up

Export Citation Format

Share Document